Publications by authors named "Tiziana Scarna"
Article Synopsis
- Measles and rubella micro-array patches (MR-MAPs) are innovative alternatives to traditional needle and syringe vaccines, offering single-dose convenience, easier handling, and better temperature stability.
- An initial full value vaccine assessment (iFVVA) evaluated their potential impact, finding that widespread use of MR-MAPs could prevent millions of measles cases, deaths, and years lost to disability by reaching an additional 80 million children over the next decade.
- The assessment also emphasized the need for financial investment in manufacturing and clinical studies, while showing that MR-MAPs have the potential to be cost-effective for routine immunization in many low- and middle-income countries, depending on pricing and coverage uncertainties.*
As an innovative vaccine delivery technology, vaccine microarray patches could have a meaningful impact on routine immunization coverage in low- and middle-income countries, and vaccine deployment during epidemics and pandemics. This review of the potential use cases for a subset of vaccine microarray patches in various stages of clinical development, including measles-rubella, measles-mumps-rubella, and typhoid conjugate, highlights the breadth of their applicability to support immunization service delivery and their potential scope of utilization within national immunization programs. Definition and assessment of the use cases for this novel vaccine presentation provide important insights for vaccine developers and policymakers into the strengths of the public health and commercial value propositions, and the preparatory requirements for public health systems for the future rollout of vaccine microarray patches.
View Article and Find Full Text PDFIntroduction: There is a need for investment in manufacturing for vaccine microarray patches (vMAPs) to accelerate vMAP development and access. vMAPs could transform vaccines deployment and reach to everyone, everywhere.
Areas Covered: We outline vMAPs' potential benefits for epidemic preparedness and for outreach in low- and lower-middle-income countries (LMICs), share lessons learned from pandemic response, and highlight that investment in manufacturing-at-risk could accelerate vMAP development.
As part of the Vaccine Innovation Prioritisation Strategy (VIPS), three immunization-stakeholder consultations were conducted between September 2018 and February 2020 to ensure that countries' needs drove the prioritization of vaccine product innovations. All consultations targeted respondents with immunization program experience. They included: (1) an online survey to identify immunization implementation barriers and desired vaccine attributes in three use settings, (2) an online survey to identify and evaluate the most important immunization challenges for ten exemplar vaccines, and (3) in-depth interviews to better understand the perceived programmatic benefits and challenges that could be addressed by nine innovations and to rank the innovations that could best address current challenges.
View Article and Find Full Text PDF